Mallinckrodt Pays $100M to Settle Price Gouging Suit

Jan 21, 2017

Bloomberg

Mallinckrodt PLC said it will pay $100 million to settle FTC charges that Questcor Pharmaceuticals illegally raised the price of its best-selling drug Acthar by 85,000 percent, and it bought the rights to a cheaper competing drug to keep it out of the U.S. market, according to a Bloomberg article.

The settlement forced Mallinckrodt to give a free limited U.S. license for that cheaper drug to a competitor, Marathon Pharmaceuticals, the story said.

The fine amounts to about a third of Acthar's quarterly sales.

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments